2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3794 Outcomes in adults with newly diagnosed post-MPN acute myeloid leukemia: The beat AML experience

Rafael Madero-Marroquin, MD, Ying Huang, MA, MS2, Olatoyosi Odenike Jr, MD3, Shivani Handa, MD4, Tara L. Lin, MD5, Eytan M Stein I, MD6, Ronan Swords, MD7, Maria R. Baer, MD8, Wendy Stock, MD9, Yazan F. Madanat, MD10, William Blum, MD11, Rebecca L Olin, MD12, Emily Curran, MD13, Gary J. Schiller, MD14, Nyla Heerema, MD15, Molly Martycz16, Mona Stefanos, MD, MBChB17, Timothy Chen, PhD18, Sonja Marcus, MPH19, John Byrd, MD20, Ross L. Levine, Prof. Dr.21, Brian Druker, MD22, Ashley Yocum, PhD23, Joshua F. Zeidner, MD24, Uma Borate, MBBS, MSc25, Alice Scott Mims, MD26, Anand Ashwin Patel, MD27
1 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
2 The Ohio State University, Columbus, Ohio, United States
3 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
4 The Ohio State University, Columbus, Ohio, United States
5 University of Kansas Medical Center, Kansas City, Kansas, United States
6 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
7 Oregon Health & Science University, Portland, Oregon, United States
8 University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
9 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
10 University of Texas Southwestern Medical Center, Dallas, Texas, United States
11 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
12 University of California San Francisco, San Francisco, California, United States
13 University of Cincinnati, Cincinnati, Ohio, United States
14 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
15 The Ohio State University, Columbus, Ohio, United States
16 The Ohio State University, Columbus, Ohio, United States
17 The Ohio State University, Columbus, Ohio, United States
18 The Ohio State University, Columbus, Ohio, United States
19 Blood Cancer United, Washington, District of Columbia, United States
20 University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
21 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
22 Oregon Health & Science University, Portland, Oregon, United States
23 Blood Cancer United, Washington, District of Columbia, United States
24 University of North Carolina, Chapel Hill, North Carolina, United States
25 The Ohio State University, Columbus, Ohio, United States
26 The Ohio State University, Columbus, Ohio, United States
27 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Introduction: Philadelphia-chromosome negative (Ph neg) myeloproliferative neoplasms (MPN) that progress to acute myeloid leukemia (AML) have poor outcomes with a median overall survival (mOS) of less than one year (Patel et al, Blood Adv 2024). Patients with post-MPN AML are frequently excluded from AML-specific clinical trials and as such there is a paucity of prospective data in this population. The Beat AML Master Trial enrolls adult patients with AML and assigns a treatment sub-study based on the molecular/cytogenetic features of the disease (Burd et al, Nat Med 2020) (NCT03013998); patients that are not assigned to a sub-study or who elect to be treated with off-protocol therapy can receive care per treating physician and are followed for survival. Beat AML includes patients with post-MPN AML; thus, we sought to characterize outcomes in this cohort.

Methods: Patients who consented to Beat AML and had an antecedent MPN reported in their medical history were eligible for inclusion; patients that had no follow-up data were not included. Descriptive statistics were utilized to summarize patient/disease characteristics and treatment approaches. Overall survival from diagnosis of AML was calculated utilizing Kaplan-Meier analysis. Of note, response data were not available for analysis.

Results: Forty patients with newly diagnosed post-MPN AML were identified; 7 patients had no treatment data available or withdrew consent for follow-up. Therefore, 33 patients were included in this analysis. Thirty-three percent had myelofibrosis, 30% had essential thrombocythemia, 21% had polycythemia vera, and 15% did not have a specified MPN subtype. Median age was 72.5 years old (range 55.5-88.2) and 58% were male. Seventy-nine percent of patients were White, 12% were Black, and 9% reported unknown/other race. Thirty-one patients had ECOG performance status noted; 68% had an ECOG of 0-1. Thirty-two patients could be risk stratified using European LeukemiaNet (ELN) 2022 criteria; 91% had adverse-risk disease. Thirty-one patients had molecular data available; 45% had adverse-risk, 26% had intermediate-risk, and 29% had favorable-risk disease by ELN 2024 criteria. Regarding MPN driver mutations, 58% had a JAK2 mutation, 10% had a CALR mutation, 3% had a MPL mutation and 29% had triple-negative disease. The most common non-driver mutations were TP53 (45%), SRSF2 (45%), RUNX1 (32%), ASXL1 (29%), NRAS (29%), IDH2 (26%), and TET2 (19%).

Regarding treatment approaches, 14 patients were treated on a Beat AML sub-study while the other 19 patients received off-protocol management per treating physician. Ten patients received hypomethylating agent (HMA) + venetoclax (Ven), 14 received other HMA-based therapies, 3 received intensive chemotherapy, 1 received IDH inhibitor monotherapy, and 5 received best supportive care. Three patients subsequently received allogeneic stem cell transplantation.

Median follow-up for the cohort was 7.7 months and estimated mOS was 10 months (95% confidence interval (CI), 4.5-18.4). When assessing the 28 patients who received AML-directed therapy, mOS was 10.4 months (95% CI, 8.11-23.2). The mOS for patients who received HMA + Ven-based therapy (n=10) compared to those treated with other lower-intensity therapies (n=15) was 8.85 months vs 10.4 months (p=0.83). When comparing patients treated on a Beat AML sub-study (n=14) to those treated with off-protocol therapy (n=14) the median OS was similar (10.3 months vs 10.2 months). Another subgroup of interest was patients treated with frontline IDH inhibitor-inclusive therapies (n=7). Therapies received included HMA + IDH inhibitor (n=5), HMA + Ven + IDH inhibitor (n=1), and IDH inhibitor monotherapy (n=1); the mOS was 23.5 months (95% CI, 8.11-not reached). Patients with a TP53 mutation (n=14) had a mOS of 3.7 months (95% CI, 2.69-not reached).

Conclusion: This retrospective analysis provides data in a cohort of patients with post-MPN AML consented to Beat AML. Median OS was 10 months, underscoring the poor outcomes in patients with post- MPN AML. Furthermore, outcomes were similar in patients treated on a Beat AML sub-study vs those treated with off-protocol therapy, underscoring the need for continued development of novel approaches and trials inclusive of this high-risk population. Of note, incorporation of IDH inhibitor-based therapy in the frontline setting for patients with IDH1/2 mutations warrants further prospective investigation.

Rafael Madero-Marroquin, MD: No relevant conflicts of interest to declare.